• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

    2/20/25 7:02:25 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRY alert in real time by email

    Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30

    SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Cigna Healthcare, Navitus Health Systems and OptumRx, through their Group Purchasing Organization (GPO) Emisar, have added neffy® (epinephrine nasal spray) to their National Formularies.

    "Millions of patients nationwide now have improved access to neffy through their commercial insurance, thanks to coverage from leading pharmaceutical benefit managers and health plans. neffy will also be available at the lowest branded copay for patients insured by OptumRx, Cigna Healthcare, and Navitus Health Systems - without the need for prior authorizations or restrictive step therapies," said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. "As a result, more patients will qualify for the low copay price of $25 for neffy, when they apply the ARS Pharma copay assistance, and healthcare providers can prescribe it without the need for additional paperwork."

    "This announcement also underscores the critical demand for a nasal spray epinephrine option within the severe allergy community and we remain committed to ensuring continued access for as many patients and caregivers as possible. While Emisar represents both OptumRx and UnitedHealthcare as their GPO at this time only OptumRx has agreed to the Emisar terms. ARS Pharma is working closely with UnitedHealthcare, as one of the country's largest healthcare providers, to add neffy to their formulary as soon as possible," said Lowenthal.

    The addition of neffy to these formularies improves coverage for the approximately 20 million people who have been diagnosed and treated for the more severe Type I allergic reactions that may lead to anaphylaxis and need epinephrine therapy to protect themselves in their daily lives. To assist patients in navigating coverage and affordability challenges, ARS Pharma offers a number of programs for patients and caregivers. For more information, visit www.neffy.com/savings.

    neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). It is the first and only FDA-approved epinephrine nasal spray that provides a needle-free alternative to traditional injectable epinephrine. It's simple and intuitive design enables rapid administration, helping patients and caregivers act quickly and confidently, and the small size is easy to carry. Additionally, neffy has a shelf-life of 30 months and temperature exclusions up to 122 degrees Fahrenheit.

    The supplemental NDA for neffy 1 mg, for children over four years of age who weigh 15 to 30 kg, has a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. Based on review timelines and subject to approval, product availability of neffy 1 mg is expected by the end of May 2025. ARS Pharma anticipates that by the epinephrine prescription renewal period, which occurs over the summer for many children in the United States, that school age children who meet the weight and age criteria will have access to neffy.

    About neffy®

    neffy is an intranasal epinephrine product for patients with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

    INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray)

    INDICATION

    neffy 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.

    IMPORTANT SAFETY INFORMATION

    It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

    neffy is for use in the nose only.

    Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

    Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

    Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

    The presence of a sulfite in neffy should not deter use.

    neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

    Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

    Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson's disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

    Adverse reactions to neffy may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting.

    These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    For additional information on neffy, please see Full Prescribing Information at www.neffy.com.

    About Type I Allergic Reactions Including Anaphylaxis

    Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency.

    About ARS Pharmaceuticals, Inc.

    ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® 2 mg (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

    Forward-Looking Statements

    Statements in this press release that are not purely historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the expected impact from the inclusion of neffy on OptumRx, Cigna Healthcare and Navitus Health Systems' National Formularies; ARS Pharmaceuticals' expectation that other payors, such as UnitedHealthcare, will agree to terms to provide access to neffy and the timing by which they will provide such access, the critical demand for a nasal spray epinephrine option, the expectation that neffy will save lives; the effectiveness of neffy; the expected timing for product availability of neffy 1 mg; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipate," "expects," "if," "may," "potential," "on track to," "plans," "will," "would," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; ARS Pharmaceuticals' reliance on its licensing partners; the ability to maintain regulatory approval for neffy in its currently approved indication and to obtain and maintain regulatory approval for neffy for additional indications; the labelling for neffy in any future indication or patient population, if approved; the scope, progress and expansion of developing and commercializing neffy; the potential for governments and payors to delay, limit or deny coverage for neffy; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharmaceuticals' ability to protect its intellectual property position; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in ARS Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission ("SEC") on November 13, 2024. These documents can also be accessed on ARS Pharmaceuticals' website at www.ars-pharma.com by clicking on the link "Financials & Filings" under the "Investors & Media" tab.

    The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharmaceuticals assumes no obligation and does not intend to update these forward-looking statements, except as required by law. For more information, visit www.ars-pharma.com, and follow us on LinkedIn and X.

    ARS Investor Contact:

    Justin Chakma

    ARS Pharmaceuticals

    [email protected]

    ARS Media Contact:

    Christy Curran

    Sam Brown Inc.

    615.414.8668

    [email protected]



    Primary Logo

    Get the next $SPRY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRY

    DatePrice TargetRatingAnalyst
    3/7/2025$30.00Sector Outperform
    Scotiabank
    2/10/2025$40.00Outperform
    Oppenheimer
    8/20/2024Overweight
    Cantor Fitzgerald
    8/13/2024$18.00 → $22.00Outperform → Strong Buy
    Raymond James
    8/12/2024$19.00 → $20.00Outperform
    Leerink Partners
    7/25/2024$18.00Outperform
    Raymond James
    3/5/2024$6.00 → $18.00Market Perform → Outperform
    Leerink Partners
    2/20/2024Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $SPRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Scott Kathleen D. exercised 50,000 shares at a strike of $1.50 and sold $705,165 worth of shares (50,000 units at $14.10) (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      5/22/25 5:00:06 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Saunders Brent L sold $1,710,024 worth of shares (120,000 units at $14.25) and exercised 120,000 shares at a strike of $1.01 (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      5/22/25 5:00:11 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Fitzpatrick Alexander A exercised 100,000 shares at a strike of $5.58 and sold $1,451,513 worth of shares (102,969 units at $14.10), decreasing direct ownership by 3% to 89,613 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      5/22/25 5:00:13 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    SEC Filings

    See more
    • SEC Form 144 filed by ARS Pharmaceuticals Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      5/20/25 4:50:59 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by ARS Pharmaceuticals Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      5/20/25 4:48:09 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ARS Pharmaceuticals Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      5/14/25 7:03:05 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SPRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

      SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June. Details outlined below. William Blair 45th Annual Growth Stock ConferencePresentation: Tuesday, June 3, 2025Time: 11:20 a.m. CTLocation: ChicagoA live webcast of the presentati

      5/27/25 8:00:44 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

      $7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

      5/14/25 7:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

      The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel and back-to-school SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced neffy® (epinephrine nasal spray) 1 mg is now available to patients and caregivers by prescription across the U.S. In March 2025, the U.S. Food and Drug

      5/7/25 8:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on ARS Pharmaceuticals with a new price target

      Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00

      3/7/25 8:14:43 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on ARS Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

      2/10/25 8:23:51 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals

      Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight

      8/20/24 8:45:44 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      6/17/24 8:47:57 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      6/11/24 7:18:55 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      3/29/24 4:14:13 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Financials

    Live finance-specific insights

    See more
    • ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

      $7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

      5/14/25 7:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

      SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A repla

      5/5/25 8:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March

      3/20/25 7:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      3/27/24 7:37:52 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Leadership Updates

    Live Leadership Updates

    See more
    • ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

      Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured

      12/19/24 5:25:09 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care